Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects

Journal of Clinical Pharmacology

Volumn 50, Issue 3, 2010, Pages 276-284

  Xu, Zhenhua ^a   Wang, Qingmin ^a   Zhuang, Yanli ^a   Frederick, Bart ^a   Yan, Hong ^a   Bouman Thio, Esther ^a   Marini, Joseph C ^a   Keen, Monica ^a   Snead, David ^a   Davis, Hugh M ^a   Zhou, Honghui ^a  

^a CENTOCOR INC   (United States)

Author keywords

Absorption; Bioavailability; Biologic; Golimumab; Human anti TNF monoclonal antibody; Pharmacokinetics; Subcutaneous

Indexed keywords

DRUG ANTIBODY; GOLIMUMAB;

ABSCESS; ADULT; AREA UNDER THE CURVE; ARTICLE; CELLULITIS; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MALE; NORMAL HUMAN; PHARYNGITIS; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; REFERENCE VALUES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77649211091     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009340782     Document Type: Article

References (27)

1. Beutler B., Cerami A. Tumor Necrosis Factors: The Molecules and Their Emerging
2. Role in Medicine. New York, NY: Raven Press Limited ; 1992.
3. Brennan FM, Maini RN, Feldmann M. TNF alpha: a pivotal role in rheumatoid arthritis ? Br J Rheumatol. 1992 ; 31: 293-298.
4. Victor FC, Gottlieb AB TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol. 2002 ; 1: 264-275.
5. Mease PJ Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 2002 ; 61: 298-304.
6. Braun J., Bollow M., Neure L., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995 ; 38: 499-505.
7. Braegger CP, Nicholls S., Murch SH, Stephens S., MacDonald TT Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992 ; 339: 89-91.
8. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991 ; 32: 913-917.
9. Cembrzynska-Nowak M., Szklarz E., Inglot AD, Teodorczyk-Injeyan JA Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis. 1993 ; 147: 291-295.
10. Scallon BJ, Moore MA, Trinh H., Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995 ; 7: 251-259.
11. Shealy D., Cai A., Staquet K., et al. Characterization of golimumab (CNTO148), a human monoclonal antibody specific for human tumor necrosis factor α. J Pharmacol Exp Ther. Submitted.
12. Bantle JP, Neal L., Frankamp LM Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993 ; 16: 1592-1597.
13. Laursen T., Jorgensen JO, Christiansen JS Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen. Clin Endocrinol (Oxf). 1994 ; 40: 373-378.
14. Jensen JD, Jensen LW, Madsen JK The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol. 1994 ; 46: 333-337.
15. Porter CJ, Charman SA Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000 ; 89: 297-310.
16. Supersaxo A., Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990 ; 7: 167-169.
17. Gibaldi M., Perrier D. Pharmacokinetics. New York, NY: Marcel Dekker ; 1982.
18. Haller CA, Cosenza ME, Sullivan JT Safety issues specific to clinical development of protein therapeutics. Clin Pharmacol Ther. 2008 ; 84: 624-627.
19. Fuzeon: package insert. Nutley, NJ: Roche Laboratories Inc ; 2008.
20. Calara F., Taylor K., Han J., et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005 ; 27: 210-215.
21. Zhou H., Jang H., Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 ; 47: 383-396.
22. Joshi A., Bauer R., Kuebler P., et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol. 2006 ; 46: 10-20.
23. Plosker GL, Keam SJ Omalizumab: a review of its use in the treatment of allergic asthma. BioDrugs. 2008 ; 22: 189-204.
24. Cvetkovic RS, Scott LJ Adalimumab: a review of its use in adult patients with rheumatoid arthritis. BioDrugs. 2006 ; 20: 293-311.
25. Porter CJ, Edwards GA, Charman SA Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev. 2001 ; 50: 157-171.
26. Radstake Trdj, Svenson M., Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009 ; 68: 1739-1745.
27. Pendley C., Schantz A., Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther. 2003 ; 5: 172-179.